Brooks Laboratories Intrinsic Value
Brooks Laboratories (BROOKS) median intrinsic value is ₹80.00 from 9 valuation models (range ₹29–₹216), vs current price ₹72.07 — +11.0% upside (Trading Below Median Value), margin of safety 9.9%. For current market price and key ratios, visit Brooks Laboratories stock price NSE.
BROOKS Valuation Methods Summary — DCF, Graham Number & P/E
Brooks Laboratories intrinsic value across 9 models vs current price ₹72.07 — upside/downside and value range per method. Browse BROOKS cash flow statement for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹216.21 | ₹172.97 - ₹259.45 | +200.0% | EPS: ₹10.84, Sector P/E: 22x |
| Book Value Method | asset | ₹65.33 | ₹58.80 - ₹71.86 | -9.4% | Book Value/Share: ₹32.67, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹80.00 | ₹72.00 - ₹88.00 | +11.0% | Revenue/Share: ₹40.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹120.00 | ₹108.00 - ₹132.00 | +66.5% | EBITDA: ₹36.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹28.83 | ₹23.06 - ₹34.60 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹69.38 | ₹62.44 - ₹76.32 | -3.7% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹167.48 | ₹150.73 - ₹184.23 | +132.4% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹144.14 | ₹129.73 - ₹158.55 | +100.0% | ROE: 32.7%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹65.33 | ₹58.80 - ₹71.86 | -9.4% | EPS: ₹10.84, BVPS: ₹32.67 |
BROOKS Intrinsic Value vs Market Price — All Valuation Models
Brooks Laboratories fair value range ₹29–₹216 vs current market price ₹72.07 across 9 valuation models. Also explore BROOKS price trends to track price trends across different timeframes.
BROOKS Intrinsic Value Analysis — Undervalued or Overvalued?
Brooks Laboratories median intrinsic value ₹80.00, current price ₹72.07 — Trading Below Median Value by 11.0%, margin of safety 9.9%.
What is the intrinsic value of BROOKS?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Brooks Laboratories (BROOKS) is ₹80.00 (median value). With the current market price of ₹72.07, this represents a +11.0% variance from our estimated fair value.
The valuation range spans from ₹28.83 to ₹216.21, indicating ₹28.83 - ₹216.21.
Is BROOKS undervalued or overvalued?
Based on our multi-method analysis, Brooks Laboratories (BROOKS) appears to be trading below median value by approximately 11.0%.
BROOKS Financial Health — Key Ratios vs Industry Benchmarks
Brooks Laboratories financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 11.33 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 32.7% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 11.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.97x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
BROOKS Cash Flow Quality — Operating & Free Cash Flow
Brooks Laboratories operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹3 Cr | ₹-20 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹-10 Cr | ₹-10 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-15 Cr | ₹-15 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-37 Cr | ₹-50 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹5 Cr | ₹3 Cr | Positive Free Cash Flow | 7/10 |